Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents.
Cook G. Bone Marrow Transplant. 2015 Aug 3. doi: 10.1038/bmt.2015.175. [Epub ahead of print].
IgG Lambda Myeloma Presenting as Plasmacytic Ascites: Case Report and Review of Literature.
Mitra S et al. Indian J Hematol Blood Transfus. 2015 Dec;31(4):472-9. doi: 10.1007/s12288-014-0454-5. Epub 2014 Sep 3.
Clinical characteristics of patients with relapsed multiple myeloma.
Dimopoulos MA et al. Cancer Treat Rev. 2015 Jul 31. pii: S0305-7372(15)00150-4. doi: 10.1016/j.ctrv.2015.07.005. [Epub ahead of print].
Lessons learnt from a case of multiple myeloma.
Vaishya R et al. BMJ Case Rep. 2015 Aug 25;2015. pii: bcr2015211358. doi: 10.1136/bcr-2015-211358.
Medical Decision-Making Incapacity among Newly Diagnosed Older Patients with Hematological Malignancy Receiving First Line Chemotherapy: A Cross-Sectional Study of Patients and Physicians.
Sugano K et al. PLoS One. 2015 Aug 21;10(8):e0136163. doi: 10.1371/journal.pone.0136163. eCollection 2015.
Immunotherapy: Engineering a sTrategy for multiple myeloma.
Razzak M. Nat Rev Cancer. 2015 Sep;15(9):514. doi: 10.1038/nrc4006. Epub 2015 Aug 20.
Multiple Myeloma Mimicking Liver Metastases.
Okamoto Y et al. Intern Med. 2015;54(16):2085-6. doi: 10.2169/internalmedicine.54.4751. Epub 2015 Aug 15.
Trends in survival of multiple myeloma: A thirty-year population-based study in a single institution.
Ríos-Tamayo R et al. Cancer Epidemiol. 2015 Aug 12. pii: S1877-7821(15)00166-6. doi: 10.1016/j.canep.2015.08.002. [Epub ahead of print].
Novel Induction Regimens in Multiple Myeloma.
Runcie KD et al. Curr Hematol Malig Rep. 2015 Aug 15. [Epub ahead of print].
How I treat high risk myeloma.
Lonial S et al. Blood. 2015 Aug 13. pii: blood-2015-06-653261. [Epub ahead of print].
Defining and treating high-risk multiple myeloma.
Usmani SZ et al. Leukemia. 2015 Aug 12. doi: 10.1038/leu.2015.209. [Epub ahead of print].
Guidelines for determination of the number of prior lines of therapy in multiple myeloma.
Rajkumar SV et al. Blood. 2015 Aug 13;126(7):921-2. doi: 10.1182/blood-2015-05-647636.
Treatment outcomes, healthcare resource utilization, and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
Kumar SK et al. Leukemia. 2015 Aug 14. doi: 10.1038/leu.2015.225. [Epub ahead of print].
Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective?
Gay F et al. Biol Blood Marrow Transplant. 2015 Aug 8. pii: S1083-8791(15)00534-0. doi: 10.1016/j.bbmt.2015.08.005. [Epub ahead of print].
Clinical treatment of newly diagnosed multiple myeloma.
Cejalvo MJ et al. Expert Rev Hematol. 2015 Aug 9:1-17. [Epub ahead of print].
Health resource utilization associated with skeletal-related events: results from a retrospective European study.
Body JJ et al. Eur J Health Econ. 2015 Aug 8. [Epub ahead of print].
An update in treatment options for multiple myeloma in nontransplant eligible patients.
Broijl A et al. Expert Opin Pharmacother. 2015 Sep;16(13):1945-57. Epub 2015 Aug 6.
Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report.
An N et al. World J Surg Oncol. 2015 Aug 7;13(1):239. doi: 10.1186/s12957-015-0649-8.
American Society of Clinical Oncology.
Alexander W. et al. P T. 2015 Aug;40(8):526-9.
Risk Management of Teratogenic Drugs～The current states of practice in Europe, US and Japan～.
Takagi T et al. Yakugaku Zasshi. 2015 Aug 3. [Epub ahead of print].